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BACKGROUND The aim of the study was to investigate 3-year major
clinical outcomes in patients(pts) with different type of lesions
treated with the zotarolimus-eluting stent (ZES) and everolimus-
eluting stent (EES) in a series of Korean population in real-world
clinical practice.
METHODS A total of 1477 consecutive pts who underwent percuta-
neous coronary intervention (PCI) with ZES or SES from April 2003 to
July 2011 were enrolled. We analyzed the overall 3-year clinical out-
comes with logistic regression, and according to left main lesion,
bifurcation, small vessel lesion (<2.25mm), calciﬁcation, ostial lesion
and diffuse long lesion (>3cm) after propensity score matching.
Further, subgroup analysis was performed for diabetics.
RESULTS In overall study population after the baseline adjustment,
there were no difference between two groups, with regard to total
death (EES vs. ZES, OR 0.932, 95%CI0.432-2.009, p¼0.857)and cardiac
death (OR0.800, 95% CI 0.314-2.042, p¼0.641), for myocardial
infarction (OR 1.426, 95% CI0.662-3.076, p¼0.365), repeated revas-
cularization (OR 0.992, 95% CI 0.667-1.474,p¼0.967), and stent
thrombosis (OR 1.212, 95% CI0.400-3.671, p¼0.734). However, in dia-
betic subgroup analysis, there was signiﬁcant reduction of repeated
revascularization in EES versus ZES (OR 0.474, 95% CI 0.232-0.971,
p¼0.041), and in bifurcation lesion (OR 0.245, 95% CI 0.070-0.865,
p¼0.029), and in calciﬁed lesion (OR 0.211, 95% CI 0.054-0.834,
p¼0.026). There were no signiﬁcant differences in total death, cardiac
death, MI, and stent thrombosis between EES and ZES in diabetics.
CONCLUSION ZES and EES showed similar safety and efﬁcacy during
3-year follow-up in patients with different type of lesions in all comer
bases. However, in diabetic patients, EES was associated with lower
incidence of repeated revascularization rate compared to ZES, espe-
cially in patients with bifurcation or calciﬁed lesions.
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BACKGROUND Several studies showed peri-contrast staining (PSS)
after DES deployment is associated with target-lesion revasculariza-
tion (TLR) and very late stent thrombosis. However, the changes of
PSS after ﬁrst generation DES to second generation DES are unclear, so
we retrospectively compare the clinical outcomes.
METHODS This study consisted of de novo 5154 lesions in 4155 pa-
tients that were treated with ﬁrst generation DES (deﬁned as siroli-
mus-eluting stent and paclitaxel-eluting stent) or second generation
DES (deﬁned as zotarolimus-eluting stent, everolimus-eluting stent,
and biolimus-eluting stent). They were evaluated by follow-up angi-
ography within 12 months after stent implantation, from April 2007 to
December 2012. We divided into PSS of ﬁrst generation DES group and
PSS of second generation DES group and compared the two groups in
clinical and angiographical outcomes.
RESULTS We had obtained 4400 lesions follow-up angiography.
(85.4%) Total late acquired PSS was observed in 90 lesions (2.0%), of
which 17 lesions was observed in the second generation DES. Baseline
clinical and angiographic characteristics were similar between the two
groups. (N.S.) The rate of PSS was higher in ﬁrst generation DES group.
(3.2% vs. 0.9%, p<0.0001) Smooth-contour PSS was highest of ﬁrst
generation DES group and mono-focal PSS was highest of second
generation DES group. (smooth contour:37.9% vs. 16.7%, mono-
focal:34.5% vs. 61.1%, p¼0.03) There was no signiﬁcant difference in
target lesion revascularization (TLR) and stent thrombosis (ST) be-
tween two groups, (N.S.) but cumulative incidence of TLR and ST in
smooth contour PSS was higher than in non-smooth contour PSS
group. (57.1% versus 21.2 %, p¼0.018 and 14.3% versus 0%, p¼0.025).CONCLUSION The occurrence of PSS decreases in second generation
DES era. Smooth contour PSS was frequently observed in the ﬁrst
generation DES and appeared to be associated with TLR and ST.
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BACKGROUND The use of a drug-eluting balloon (DEB) for the
treatment of de novo non-small vessel coronary artery diseases (CAD)
remains to be evaluated. A previous trial which compared a bare metal
stent mounted on a DEB to a sirolimus-eluting stent failed to meet the
prespeciﬁed non-inferiority criteria and showed unexpected increase
of myocardial infarction (MI). The stent struts of a BMS pre-mounted
on a DEB might prevent an adequate delivery of the drug to the vessel
wall. Therefore, we evaluated the efﬁcacy of a sequential DEB and
BMS application for treating de novo coronary lesion in comparison to
a zotarolimus-eluting stent (ZES) in the present study.
METHODS The DEB First study is a prospective, randomized, open-
label study. We designed it to demonstrate the non-inferiority of a
DEB (SequentPlease, B. Braun) ﬁrst followed by a BMS (Coroﬂex
Blue, B. Braun) (DEB-BMS)compared with a ZES (Resolute Integrity,
Boston Scientiﬁc).We used a longer DEB ﬁrst by 5 mm to treat the full
length of a lesion than a BMS to dilate residual stenosis or dissection
ﬂap after DEB. Eligible lesion were de novo coronary artery diseases in
patients with stable angina, unstable angina or non-ST segment
elevation myocardial infarction. The primary endpoint of the study is
in-segment late loss (LL) at 9 months measured by quantitative cor-
onary angiography. Secondary endpoints include other angiographic
ﬁnding sand clinical outcomes such as procedural success, all cause
death, MI, target vessel revascularization, target lesion revasculari-
zation, and stent thrombosis.
RESULTS A total of 180 patients were enrolled in the present study.
Among 90 patients randomized to DEB-BMS, 2 patients received ZES
due to DEB delivery failure. There was no procedural or angiographic
failure in the both groups. Mean procedure time  SD was 58.623.1 vs
55.118.5 in DEB-BMS vs ZES (minutes, p¼0.263). Stent length was
17.14.3 mm vs 22.26.4mm (p<0.001) and post-PCI minimal lesion
diameter was 2.500.44 mm vs 2.610.42mm (p¼0.097). There was
one clinical follow-up loss in DEB-BMS at 9 months. Death occurred in
a patient (1.1%) in DEB-BMS (non-cardiac) and in two patients (2.2%)
in ZES (cardiac). There was no myocardial infarction in the both
groups. Target lesion revascularization was done in 6 patients (6.7%)
in DEB-BMS and in 2 patients (2.2%) with ZES. Nine month follow-up
angiography was done in 75 patients with DEB-BMS and 72 patients
with ZES. Late loss was 0.520.44 in DEB-BMS vs. 0.260.36 in ZES
(p<0.001). One-sided 97.5% conﬁdence interval of the late loss dif-
ference was 0.11 – 0.41 (p¼0.990).
